Modhi Gude, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1346272523
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,869 of the $3,314 with a category attached, or 86.6%. 22 manufacturers reported payments, led by AstraZeneca at 36.0% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.
Across 160 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$447
- Tandem Diabetes Care, Inc.$400
- Abbott$266
- Novo Nordisk$158
- Boehringer Ingelheim$144
- plus $707 from 16 others
What the payments were for
- Speaking & faculty fees$40012%
- Food & beverage$2,86987%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,192 |
| Lilly USA, LLC | 40 | $447 |
| Tandem Diabetes Care, Inc. | 1 | $400 |
| Abbott | 2 | $266 |
| Novo Nordisk | 8 | $158 |
| Boehringer Ingelheim | 8 | $144 |
| AbbVie | 6 | $101 |
| Antares Pharma, Inc. | 5 | $98 |
| Amgen | 3 | $83 |
| Madrigal Pharmaceuticals | 2 | $79 |
| Chiesi USA, Inc. | 2 | $56 |
| Corcept Therapeutics | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| IBSA Pharma Inc. | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,314 in reported general payments places this provider in the 50th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $210,985 |
| JardianceEmpagliflozin | 99 | $121,031 |
| MounjaroTirzepatide | 92 | $109,742 |
| TrulicityDulaglutide | 31 | $54,443 |
| OmnitropeSomatropin | 22 | $53,995 |
| FarxigaDapagliflozin Propanediol | 40 | $50,506 |
| GenotropinSomatropin | 13 | $44,902 |
| TymlosAbaloparatide | 12 | $31,228 |
| JanuviaSitagliptin Phosphate | 25 | $24,995 |
| TradjentaLinagliptin | 14 | $21,777 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $18,822 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $17,045 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $16,763 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $14,358 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $12,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $158 | $210,985155 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $447 | $166,588135 claims |
| Boehringer IngelheimJardiance, Tradjenta | $144 | $142,808113 claims |
| AstraZenecaFarxiga | $1,192 | $50,50640 claims |
| MerckJanuvia, Janumet | $14 | $39,35345 claims |
| Radius Health, Inc.Tymlos | $26 | $31,22812 claims |
| AbbVieSynthroid | $101 | $7,40876 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.